When a weekly injection becomes a mass-market product, somebody has to make the hundreds of millions of pens, needles, vials, and seals that go with it. These are not household names, and the parts are tiny — a rubber stopper, a glass cartridge, an auto-injector spring — but the injection boom turned drug delivery devices and components into a growth business. It also handed that business a clear long-term question: what happens when patients switch to a pill?
Part 4 of 8
Pens, needles & components
4 Jun 2026Drug delivery devices: the GLP-1 components business
The quiet winners of the injection boom — West Pharmaceutical, Becton Dickinson — who make the pens, needles, and components, and how the pill threatens them.
Dual guardrail: this article is information only. It is not medical advice and not investment advice. Speak to a locally regulated professional before acting on anything you read.
Key Takeaways
- 1This article covers key developments in the crypto market
- 2Always verify claims with official FCA and regulatory sources
- 3Past performance does not guarantee future results
- 4Consider speaking to a qualified financial adviser before acting
- 5TradeRadarNews provides information only — not financial advice
Every injection needs a pen, a needle, and precision-made components. The delivery link is a quiet beneficiary of the boom — and one with a clear threat on the horizon.
Where this sits in the ripple
Duopoly · Pill · Factory · Delivery · Access · Consumer ripple · Healthcare ripple · Forces
Delivery sits between The Factory and the patient. Links up to The Boom. These businesses belong to the wider medical-devices link in our Healthcare series.
What this link is
- Primary packaging / containment — the components that physically touch the drug: stoppers, seals, cartridges. They must be inert, sterile, and flawlessly consistent, which makes suppliers hard to switch.
- Auto-injector pen — the self-contained device a patient uses to dose without a syringe.
- Why the oral shift matters here. A pill needs none of this injection hardware. So the same trend that could expand the overall market (the oral race) is a direct threat to the delivery link's growth.
The companies
West Pharmaceutical Services (WST)
What they do: makes the elastomer (rubber) components and containment systems that injectable drugs depend on — the unseen parts inside every pen and vial. The numbers:. The edge: an entrenched, heavily regulated supplier whose components are designed into products and certified alongside them — switching is slow and costly. The risk: a faster-than-expected move to oral GLP-1s would erode demand for injection components, the very thing driving its recent growth.
Becton Dickinson (BDX)
What they do: makes needles, syringes, and drug-delivery systems at vast scale, across healthcare. The numbers:. The edge: breadth and manufacturing scale across injection hardware, with a diversified medical-products base beyond GLP-1s. The risk: the same oral-shift threat to injection volumes, layered on top of the broader cyclicality of hospital and medical-product spending.
Context, not profiles. Europe's Gerresheimer, Ypsomed, and Stevanato are significant pen and component makers, but sit outside the US index.
The bull and bear case
The bull case: injectables still dominate today, and as long as they do, rising volumes lift demand for the indispensable components behind them — a steady, picks-and-shovels position.
The bear case: the pill is a structural threat. If oral GLP-1s take a large share of the market, the delivery link's growth story weakens even as the overall drug market expands.
What feeds it, what it feeds
Delivery hardware is fed by The Factory and carries the drug to the patient — but the patient still has to obtain it. That is the next ring: The Access Layer. Back to the map: The Boom.
This article is for information only. It is not medical advice and not investment advice or a recommendation to buy or sell any security. TradeRadarNews is not a licensed financial or medical adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consult a locally regulated professional.
Risk Warning: Trading and investing carries significant risk. Your investments can fall as well as rise. CFDs carry high risk of rapid loss due to leverage. Cryptocurrency is not FCA-regulated and not covered by FSCS. This is information only, not financial advice. Seek independent advice before investing.
Written by
TradeRadarNews Team
Editorial Team
Our editorial team covers markets, fintech, and regulatory developments across the UK and globally.